Found 213 chains in Genus chains table. Displaying 1 - 50. Applied filters: Proteins

Search results query ec: 3.4.21.21

Total Genus Sequence Length pdb Title
41 254 8cn9C Factor vii binding fab of the bispecific antibody hmb-001 in complex with factor vii
13 94 8cn9D Factor vii binding fab of the bispecific antibody hmb-001 in complex with factor vii
3 46 1f7eA The first egf-like domain from human blood coagulation fvii, nmr, 20 structures
4 46 1ff7A The first egf-like domain from human blood coagulation fvii (fucosylated at ser-60), nmr, 20 structures
6 41 1bf9A N-terminal egf-like domain from human factor vii, nmr, 23 structures
8 37 5ky3B Mouse pofut1 in complex with mouse factor vii egf1 mutant (t101a) and gdp-fucose
12 55 5l2yL Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid
60 254 5l30H Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
59 254 5l2yH Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,20-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl] cyclobutane-1-carboxylic acid
10 40 5ky2B Mouse pofut1 in complex with o-glucosylated mouse factor vii egf1 and gdp
13 56 5l30L Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(1h-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
8 38 5kxhB Mouse pofut1 in complex with mouse factor vii egf1 and gdp
13 58 5l2zL Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid
59 254 5l2zH Factor viia in complex with the inhibitor 1-[(2r,15r)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid
9 39 5l0sB Human poglut1 in complex with factor vii egf1 and udp
60 254 5i46H Factor viia in complex with the inhibitor (2r,15r)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione
29 144 4zmaL Crystal structure of a fviia-trypsin chimera (st) in complex with soluble tissue factor
60 249 4zmaH Crystal structure of a fviia-trypsin chimera (st) in complex with soluble tissue factor
63 249 4z6aH Crystal structure of a fviia-trypsin chimera (yt) in complex with soluble tissue factor
12 57 4yt7L Factor viia in complex with the inhibitor 2-(2-{(r)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1h-imidazol-4-yl)benzamide
19 96 4z6aL Crystal structure of a fviia-trypsin chimera (yt) in complex with soluble tissue factor
61 254 4yt7H Factor viia in complex with the inhibitor 2-(2-{(r)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1h-imidazol-4-yl)benzamide
56 254 3th2H Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
27 142 3th2L Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
53 254 3th3H Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
54 254 3th4H Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
28 142 3th4L Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
17 96 3th3L Mg2+ is required for optimal folding of the gamma-carboxyglutamic acid (gla) domains of vitamin k-dependent clotting factors at physiological ca2+
12 55 5u6jL Factor viia in complex with the inhibitor 3-{[(2r)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide
61 254 5u6jH Factor viia in complex with the inhibitor 3-{[(2r)-17-ethyl-4-methyl-3,12-dioxo-7-[(propan-2-yl)sulfonyl]-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaen-2-yl]amino}benzamide
59 254 5tqeH Factor viia in complex with the inhibitor (5r)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione
12 55 5tqeL Factor viia in complex with the inhibitor (5r)-5-[(1-aminoisoquinolin-6-yl)amino]-19-(cyclopropylsulfonyl)-3-methyl-13-oxa-3,15-diazatricyclo[14.3.1.1~6,10~]henicosa-1(20),6(21),7,9,16,18-hexaene-4,14-dione
59 254 5tqfH Factor viia in complex with the inhibitor (11r)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
11 55 5tqgL Factor viia in complex with the inhibitor (5r,11r)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
59 254 5tqgH Factor viia in complex with the inhibitor (5r,11r)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
12 55 5tqfL Factor viia in complex with the inhibitor (11r)-11-[(1-aminoisoquinolin-6-yl)amino]-16-(cyclopropylsulfonyl)-13-methyl-2,13-diazatricyclo[13.3.1.1~6,10~]icosa-1(19),6(20),7,9,15,17-hexaene-3,12-dione
64 254 5parC Crystal structure of factor viia in complex with 1h-benzimidazol-2-amine
63 254 5pasC Crystal structure of factor viia in complex with (2s)-2-hydroxy-n-[[3-[5-hydroxy-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-phenylpropanamide
63 254 5pawB Crystal structure of factor viia in complex with isoquinoline-1,6-diamine
63 254 5paiB Human factor viia in complex with n-(2-amino-1h-benzimidazol-5-yl)-1-[3-[[(3,5-dimethyl-1,2-oxazol-4-yl)carbamoylamino]methyl]phenyl]-5-hydroxypyrazole-4-carboxamide at 1.73a
14 58 5paaA Crystal structure of factor viia in complex with cyclohexylmethanamine
62 254 5pb2C Crystal structure of factor viia in complex with 2-phenyl-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-3-ol
13 58 5pauA Crystal structure of factor viia in complex with n-(2-amino-1h-benzimidazol-5-yl)-2-[3-[(2-amino-2-oxoethyl)-methylsulfonylamino]phenyl]acetamide;2,2,2-trifluoroacetic acid
64 254 5pagB Crystal structure of factor viia in complex with (2r)-2-hydroxy-n-[[3-[5-hydroxy-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]-3-methylbutanamide;hydrobromide
66 254 5paaC Crystal structure of factor viia in complex with cyclohexylmethanamine
13 58 5pamA Crystal structure of factor viia in complex with 2-[(1-aminoisoquinolin-6-yl)amino]-2-(5-ethoxy-2-fluorophenyl)-1-(2-phenylpyrrolidin-1-yl)ethanone
12 55 5pabL Crystal structure of factor viia in complex with 1-[[3-[2-hydroxy-3-(1h-pyrrolo[3,2-c]pyridin-2-yl)phenyl]phenyl]methyl]-3-phenylurea
12 56 5paeA Crystal structure of factor viia in complex with (2s)-2-hydroxy-n-[[3-[5-hydroxy-4-(1h-pyrrolo[3,2-c]pyridin-2-yl)pyrazol-1-yl]phenyl]methyl]propanamide
64 254 5pb3C Crystal structure of factor viia in complex with 1-[[3-[4-(5-amino-1h-pyrrolo[3,2-b]pyridin-2-yl)-5-hydroxypyrazol-1-yl]phenyl]methyl]-3-phenylurea
13 57 5pakA Crystal structure of factor viia in complex with n-[[4-(aminomethyl)-2-(2-amino-2-oxoethoxy)phenyl]methyl]-2-(4-hydroxyphenyl)-2-methoxyacetamide;hydrochloride